Neuroinflammation in Hypertension Study

Royal Perth Hospital60 enrolled

Overview

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Resistant Hypertension

Interventions

MinocyclineDRUG

Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo. Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Eligibility

Sex: ALLMin age: 45 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged: 45 -65 years * Signed informed consent * Clinical diagnosis of Resistant Hypertension * Daytime systolic ambulatory BP \>135mmHg. Exclusion Criteria:• eGFR of \<45 mL/min/1.73m2 * History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias, * current of past history of heart failure (LVEF ≤40%) * psychotropic agents, antidepressants and NSAIDS * alcohol consumption of \>3 standard drinks. * known hypersensitivity or contraindication to minocycline or other tetracyclines.

Locations (1)

Royal Perth Hospital

Perth, Western Australia, Australia

RECRUITING

Outcomes

Primary Outcomes

The difference in the daytime systolic blood pressure between groups after respective treatment.

Office and ambulatory blood pressures

Time frame: 12 weeks

Assessment of change in central and peripheral inflammation

FDG PET

Time frame: 12 weeks

Secondary Outcomes

Change in muscle sympathetic nerve activity

Muscle sympathetic nerve activity assessed by microneurography

Time frame: 12 weeks

Change in central Blood Pressure

central Blood Pressure assessed by Sphygmocor XCEL

Time frame: 12 weeks

Central Contacts

Revathy Carnagarin, MD

CONTACT

+61892240316 revathy.carnagarin@uwa.edu.au

Omar Azzam, MD

CONTACT

+61892242244 omar.azzam@health.wa.gov.au

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.